Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10257481
ABSTRACT:
The present invention relates to the new use of bradycardiac substances such as a Ca++channel blocker, beta-receptor blocker or ifchannel blocker, the ifchannel blockers being preferred, optionally in combination with a cardioactive substance for inducing the regression of myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic pets.
REFERENCES:
patent: 5175157 (1992-12-01), Psiorz et al.
patent: 5308853 (1994-05-01), Hodges et al.
patent: 5516773 (1996-05-01), Rose
patent: 5595987 (1997-01-01), Lasker et al.
patent: 5721217 (1998-02-01), Liu et al.
patent: 5968978 (1999-10-01), Kleemann et al.
patent: 6083991 (2000-07-01), Bergeron, Jr.
patent: 2004/0138306 (2004-07-01), Guth et al.
patent: 2435526 (2004-01-01), None
patent: 3541811 (1987-06-01), None
patent: 0 224 794 (1987-06-01), None
patent: 0330052 (1989-08-01), None
patent: 0 471 388 (1992-02-01), None
patent: WO 00/02543 (2000-01-01), None
patent: WO 01/78699 (2001-04-01), None
patent: WO 0178699 (2001-10-01), None
Toshiima et al “Comparable effects of oral dilitazem and verapamil in the treatment of hypertrophic cardiomyopathy”, Japanese Heart Journal, Bd. 27, Nr. 5, 1986, 701-715.
Merck Index, 12thEd., 1996, pp. 541 and 1696.
The Merck Manual, 15thEdition, 1987, pp. 519-522.
Rieu et al, Eur. J. Med. Chem. 1993, 28, 683-691.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
P. Gregor, et al; Use of Verapamil in the Treatment of Hypertrophic Cardiomyopathy, Cor Et Vasa, Bd. 28 Nr. 6, 1986, pp. 404-412, XP 001024692.
A. Hartmann, et al; Persisting effect of Calcium-channel blockers on the left ventricular function in hypertrophic cardiomyopathy after 14 years' treatment, Angiology, Bd. 47, Nr. 8, 1996 pp. 765-773- XP 00124817.
H. Toshima, et al; Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy, Japanese Heart Journal, Bd. 27, Nr. 5, 1986 pp. 701-715, XP0010214687.
G. Kober, et al; Clinical cardiology hypertrophic cardiomyopathy. Long-term verapamil versus propranolol treatment of hypertrophic cardiomyopathy in matched pairs of patients, Circulation Supplement, Abstracts from the 60th Scientific Session Bd. 76, Nr. 4, 1987 p. IV-248-XP001024696.
S.E. Epstein, et al; Verapamil; Its potential for causing serious complications in patients with hypertrophic cardiomyopathy; Circulation, Bd. 64, Nr. 3, 1981, pp. 437-441 XP001024694.
Database WPI, Section PQ, Week 199747 Derwent Publications Ltd. London, GB; Class P31; AN 1997-510672, XP 002179143.
The Extra Pharmacopoeia, 30th Edition, The Pharmaceutical Press, London, XP 002179142, p. 668.
T. Shinke, et al; Beneficial effects of heart rate reduction on cardiac mechanics and energetics in patients with left ventricular dysfunction, Japanese Circulation Journal, English Edition, vol. 63, No. 12 pp. 957-964.
J.P. Rieu, et al; Synthesis and bradycardia activity of a series of substituted 3-aminoalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones as potent antiischemics, Europena Journal of Medicinal Chemistry, vol. 28, No. 9, pp. 683-691.
D.P. Nichols, et al; Cardio Vascular effects of Alinidine and Propranolol alone and in combination with Hydralazine in Normal Man, Br. J. Clin. Pharmacol, (1983) 15 (1), 21-30-XP001041903.
International Search Report Dec. 13, 2001.
Muller, C. A. et al.; Combination of a Calcium Antagonist, Verapamil, with an Angiotensin Converting Enzyme Inhibitor, Trandolapril, in Experimental Myocardial Ischemia and Reporfusion; Antiarrhythmic and Hermodynamic Effects of Chronic Oral Pretreatment); Cardiovascular Drugs and Therapy 1998; 12:449-455;Kluwer Academic Publishers, Boston.
Ruschitzka, F.T., et. al.: Combination of ACE Inhibitors and Calcium Antagonists: A logical approach;J Cardiovasc Pharmacol, vol. 31 Supplement 2, 1998, pp. S5-S16.
The Merck Manual, 1987, 15th Edition, pp. 519-522.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
Granetzny, A., et al., “Pharmacologic heart rate reduction: effect of a novel specific bradyardic agent on the heart,” The Thoracic and Cardiovascular Surgeon, vol. 46, 1998, pp. 63-69.
Lijnen, P. and Petrov, V: Renin-Anglotensin System, Hpertrophy and Gene Expression in Cardiac Myocytes; J. Mol Cell Cardiol, 31, pp. 949-970 (1999).
Stark, M., et al. Method for Improving Diagnostic Quality in Echocardiography; U.S. Appl. No. 11/470,303, filed Sep. 6, 2006.
U.S. Appl. No. 11/273,221, filed Nov. 14, 2005, first Inventor Brian Guth.
Gregor, P., et al.: Use of Verapamil In the Treatment of Hypertrophic Cardiomyopathy, Cor Et Vasa, vol. 28, No. 6, 1986, pp. 404-412.
Hartmann, A. et al: Persisting effect of Calcium-channel blockers on the left ventricular function in hypertrophic cardiomyopathy after 14 years' treatment, Anglology, vol. 47, No. 8, 1996 pp. 765-773.
Kober, G., et al: Clinical cardiology hypertrophic cardiomyopathy, Long-term verapamil versus propranolol treatment of hypertrophic cardiomyopathy in matched pairs of patients. Circulation Supplement, Abstracts from the 60th Scientific Session vol. 76, No. 4, 1987 p. IV-248.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
Epstein, S.E., et al; Verapamil: Its potential for causing serious complications in pateients with hypertrophic cardiomyopathy; Circulation, 1981; 64, pp. 437-441.
Database WPI, Section PQ. Week 199747 Derwent Publications Ltd. London, GB; Class P31; AN 1997-510672KOVTUN, et al: Determination of clinical efficiency of drugs used to treat hypertrophic cardiomyopathy using coefficient based on speed of movement of mitral valve, reflecting diastolic function of left ventricie, and stroke volume left auricle.
The Extra Pharmacopoeia, 30th Edition, The Pharmaceutical Press, London p. 668.
Nicholls, D.P., et al; Cardio Vascular effects of Alinidine and Propranolol alone and in combination with Hydralazine In Norman Man, Br. J. Clin. Pharmacol, (1983) 15 (1), 21-29.
Daemmgen Juergen
Guth Brian
Seidler Randolph
Blankinship Thomas
Boehringer Ingelheim Pharma GmbH & Co. KG
Devlin Mary-Ellen M.
Jiang Shaojia Anna
Krishnan Ganapathy
LandOfFree
Use of bradycardiac substances in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of bradycardiac substances in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bradycardiac substances in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3790221